FDA Expands Use of Organon Arthritis Biosimilar Tofidence

The FDA has authorized Organon's Tofidence biosimilar to treat cytokine release syndrome in cancer patients and COVID-19 in patients requiring respiratory support. This expansion allows the drug to be used in adults and children aged two and older for these life-threatening conditions.